Integra LifeSciences (NASDAQ:IART) Stock Price Up 4.9% - What's Next?

Key Points

• Integra LifeSciences' stock price rose 4.9% to $14.30, with approximately 384,989 shares traded, indicating a significant decline from its average daily volume.
• The company reported quarterly earnings of $0.45 per share, exceeding analysts' expectations of $0.43, and total revenue of $415.61 million, up from predictions of $395.06 million.
• Institutional investors own 84.78% of Integra LifeSciences' stock, with significant increases in holdings from various firms during the second quarter.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report)'s stock price rose 4.9% on Tuesday . The company traded as high as $14.24 and last traded at $14.30. Approximately 384,989 shares were traded during trading, a decline of 63% from the average daily volume of 1,052,766 shares. The stock had previously closed at $13.63.

Integra LifeSciences Price Performance

The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18. The stock's 50-day simple moving average is $14.04 and its two-hundred day simple moving average is $14.79. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of -2.19 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. The company had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm's revenue for the quarter was down .6% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 earnings per share. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Equities research analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Large investors have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its holdings in shares of Integra LifeSciences by 205.9% during the second quarter. Caitong International Asset Management Co. Ltd now owns 3,132 shares of the life sciences company's stock worth $38,000 after buying an additional 2,108 shares in the last quarter. Osaic Holdings Inc. grew its holdings in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company's stock worth $51,000 after buying an additional 1,104 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of Integra LifeSciences during the second quarter worth $73,000. EMC Capital Management purchased a new stake in shares of Integra LifeSciences during the second quarter worth $75,000. Finally, CWM LLC grew its holdings in shares of Integra LifeSciences by 413.8% during the first quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock worth $147,000 after buying an additional 5,367 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.